Name: Latest research reports of Glenmark Pharmaceuticals Ltd. authored by Phillip Capital and published by - Trendlyne research reports.
Item: Glenmark Pharmaceuticals Ltd.
Rating: 3
Author: Phillip Capital

Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
24 Sep 2025	Glenmark Pharma	Consensus Share Price Target	2022.20	2254.50	-	11.49	buy	pdf Detailed Estimates
03 Aug 2015	Glenmark Pharma	Phillip Capital Reco Target	2022.20	940.00	989.75 (104.31%)		Neutral	pdf post cache	Broker Report Glenmark 3Aug2015 Phillip Capital company maintained its sales growth guidance of 1820% and EBITDA of ~Rs 17.5bn (implying ~22% margin) on a presumed ramp up in US generic sales and continued momentum in domestic formulations. However, modest US sales growth (8.5%) in Q1... pdf Copy Link Share on Share on Share on Share on Alert
03 Jun 2015	Glenmark Pharma	Phillip Capital	2022.20	975.00	853.80 (136.85%)	Target met	Buy	pdf post cache	Broker Report Glenmark 3June2015 Phillip Capital broadbased improvement in US sales (20%), domestic formulations (1719%), and in EuropeandROWmarkets.IttargetsanEBITDAofRs17.5bn,implyingamarginof~22% (lower than our estimate of 22.7%) and tax incidence of 2324% (we factored 22%). The... pdf Copy Link Share on Share on Share on Share on Alert
22 Apr 2014	Glenmark Pharma	Reliance Securities	2022.20	709.00	574.50 (251.99%)	Target met	Buy	pdf post cache	Broker Report Glenmark Pharmaceuticals Reliance Securities Background: Tarka is a hypertension drug with market size of US$70mn. Glenmark had launched the drug "at-risk" in June 2010. However, the Federal Jury ruled against Glenmark in January 2011 and awarded Abbott US$16mn in... pdf Copy Link Share on Share on Share on Share on Alert
27 Sep 2013	Glenmark Pharma	Ashika Research	2022.20	610.00	522.85 (286.76%)	Target met	Buy	pdf post cache	Broker Report Glenmark Pharma Limited Ashika Research Glenmark pharma's (GNP) Q1FY14 revenues grew 19% YoY to Rs. 1238.2 cr driven by 33% growth in Latin America (specialty business), 25% growth in RoW markets, 26% growth in API... pdf Copy Link Share on Share on Share on Share on Alert
15 May 2012	Glenmark Pharma	Ashika Research	2022.20	410.00	365.35 (453.50%)	Target met	Buy	pdf post cache	Broker Report Glenmark Pharmaceuticals Ltd Ashika Research Glenmark Pharmaceuticals Ltd(GPL) is a research driven, integrated pharma company that has presence in both Generic and API business. The company is a leading player in the discovery of new molecules both new chemical... pdf Copy Link Share on Share on Share on Share on Alert

58.54% Gain from 52W Low

Glenmark Pharmaceuticals Ltd. share price target

Glenmark Pharmaceuticals Ltd. has an average share price target of 2144. The consensus estimate represents an upside of 6.02% from the last price of 2022.20. View 11 reports from 5 analysts offering long-term price targets for Glenmark Pharmaceuticals Ltd..

Glenmark 3Aug2015

Glenmark 3June2015

Glenmark Pharmaceuticals

Glenmark Pharma Limited

Glenmark Pharmaceuticals Ltd

Advisor Screeners